Rueil Malmaison, France

Sylvie Berrard


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2001-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sylvie Berrard: Innovator in Cholinergic Protein Research

Introduction

Sylvie Berrard is a notable inventor based in Rueil Malmaison, France. She has made significant contributions to the field of molecular biology, particularly in the area of cholinergic proteins. With a total of 2 patents, her work has implications for therapeutic applications.

Latest Patents

Berrard's latest patents include innovative approaches to gene expression inhibition and protein transport. One of her patents, titled "RNAi mediated expression inhibition of a cholinergic protein," focuses on nucleic acid sequences that produce functional miRNA, shRNA, and siRNA designed to silence the expression of genes encoding cholinergic proteins. This invention also encompasses compositions and kits that utilize these nucleic acid sequences. Another significant patent is "Recombinant expression of the rat vesicular acetylcholine transporter," which discloses a nucleic sequence coding for a protein involved in the vesicular transport of acetylcholine. This patent includes expression vectors containing the sequence and discusses the therapeutic uses of these vectors.

Career Highlights

Throughout her career, Sylvie Berrard has worked with esteemed organizations such as the Centre National de la Recherche Scientifique and Rhône-Poulenc Rorer S.A. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community.

Collaborations

Berrard has collaborated with notable colleagues, including Jacques Mallet and Marie José Lecomte. These partnerships have enriched her research and expanded the impact of her inventions.

Conclusion

Sylvie Berrard's innovative work in the field of cholinergic proteins and her contributions to molecular biology highlight her role as a significant inventor. Her patents reflect her commitment to advancing scientific knowledge and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…